+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 20 Actively Recruiting clinical trials

T

Actively Recruiting

Researchers are evaluating a new tuberculosis preventive treatment among adolescents and school staff who have been in close contact with active TB cases. This study compares a novel 1-month ultra-short regimen called 1H3P3 with the standard 3-month 3HR regimen, aiming to prevent latent TB infection from progressing to active tuberculosis. The trial is a phase 3, multi-center, open-label, cluster randomized controlled study conducted in school settings in China, with the goal of improving TB prevention strategies for adolescents. Participants are randomly assigned to receive either the 12-dose 1H3P3 regimen of isoniazid and rifapentine taken three times a week for one month, or the 3HR regimen of isoniazid and rifampicin taken once daily for three months. Close contacts of TB cases are screened using blood tests, chest X-rays, sputum testing, and symptom checks to rule out active TB before enrollment. The treatment period lasts either one or three months depending on the group, followed by two years of follow-up to monitor for TB development. During the study, participants will undergo regular assessments including monitoring for active tuberculosis through clinical and laboratory tests, adverse events, treatment adherence, and drug resistance if active TB occurs. The main measurement is the cumulative incidence of active TB over 24 months after treatment begins. Safety and treatment completion rates are tracked throughout. Participation involves screening, treatment administration, and periodic follow-up visits over two years to evaluate outcomes and overall TB prevention effectiveness.

Age: 13Years +All GendersPhase 3
66 locations
E

Actively Recruiting

Researchers are evaluating the efficacy, safety, and tolerability of balcinrenone combined with dapagliflozin compared to dapagliflozin alone in adults with chronic kidney disease CKD Stage 3b and 4, who have an estimated glomerular filtration rate eGFR between 15 and less than 45 mLmin1.73 m2. This Phase III study focuses on a population with high unmet medical needs and increased risk of CKD progression, often excluded from other trials. The main goal is to see if the combination reduces cardiovascular death, kidney failure, and heart failure events. Participants will be randomly assigned to one of two groups one receiving a daily capsule containing balcinrenone 15 mg and dapagliflozin 10 mg plus a placebo tablet matching dapagliflozin, and the other receiving a dapagliflozin 10 mg tablet plus a placebo capsule matching balcinrenonedapagliflozin. All treatments are taken orally once daily alongside standard of care therapy. The study is conducted globally at approximately 550 sites in about 30 countries. During the study, participants will be monitored for up to 46 months to track outcomes such as cardiovascular death, kidney failure, and decline in kidney function measured by eGFR. Researchers will also assess changes in urinary albumin to creatinine ratio and overall safety and tolerability. Participants will have regular visits for assessments including laboratory tests and clinical evaluations to measure these outcomes and monitor health status throughout the study.

Age: 18Years - 99YearsAll GendersPhase 3
478 locations
A

Actively Recruiting

Researchers are conducting a prospective, multicenter, observational registry study to better understand treatment approaches, clinical practice changes, and cardiorenal risk outcomes in Chinese patients with chronic kidney disease CKD. This study aims to collect real-world data from about 3000 participants across various hospital types and geographic regions in China, reflecting diverse clinical care settings. Participants diagnosed with CKD will be enrolled and followed for up to 96 weeks. Data will be gathered at multiple sites including top-tier tertiary hospitals, regional medical centers, and secondary hospitals. Information will be collected from medical records and entered into a cloud-based electronic system to ensure quality and accuracy. The study does not involve administering treatments but observes existing clinical practices. During the study, investigators will monitor clinical indicators and outcomes related to CKD and associated conditions such as hypertension, heart failure, and hyperkalemia over the 96-week period. Medication use and changes in treatment strategies will be tracked. Participants will provide informed consent before enrollment and their health data will be regularly reviewed to assess long-term outcomes and treatment patterns.

All AgesAll Genders
59 locations
E

Actively Recruiting

Researchers are evaluating the effect of E6742, an oral drug, compared with a placebo in adults with systemic lupus erythematosus SLE. This phase 2, randomized, double-blind, placebo-controlled study aims to assess how different doses of E6742 influence the proportion of participants achieving a response using the British Isles Lupus Assessment Group BILAG based Composite Lupus Assessment BICLA while using a low dose of oral corticosteroids at Week 24. Participants will be randomly assigned to receive one of several doses of E6742 or a placebo in oral tablet form. The treatment period involves administering these doses while monitoring participants for up to 24 weeks. The study evaluates the efficacy based on dose response, as well as safety measures including adverse events, laboratory tests, vital signs, and various clinical assessments during this time. Throughout the study, participants will undergo multiple evaluations including clinical assessments like SLEDAI-2K, BILAG-2004, patient-reported outcomes, and laboratory tests such as autoantibody levels and complements. Safety will be monitored via vital signs, ECGs, ophthalmic exams, and chest X-rays. The primary outcome is measured at Week 24, with safety and secondary outcomes assessed up to 52 weeks. Participants are expected to comply with study visits and treatments over this period.

Age: 18Years - 75YearsAll GendersPhase 2
54 locations
P

Actively Recruiting

Researchers are evaluating SCTB35 in patients with systemic lupus erythematosus SLE through a multicenter Phase IbII clinical trial. The study aims to assess the safety, tolerability, pharmacokinetics, and preliminary effectiveness of SCTB35 in this patient group. The trial includes both dose-escalation and dose-expansion phases to identify optimal dosing and compare safety and efficacy at recommended dose levels. The study involves administering SCTB35 by subcutaneous injection every 21 days in treatment cycles. During the dose-escalation phase, different dose levels are tested to find the maximum tolerated dose and recommended Phase II dose, with safety data reviewed by a committee. Once the recommended dose is confirmed, expansion cohorts will further evaluate SCTB35 at those doses. Participants will undergo regular assessments including monitoring for adverse events up to 24 weeks, and evaluation of disease activity using measures such as the SLE Responder Index-4, SLEDAI-2K, and physician global assessment. Additional evaluations include immunogenicity and other lupus activity scores up to 52 weeks. The study involves informed consent and contraception requirements, with ongoing safety and efficacy monitoring throughout participation, which lasts up to at least 24 weeks.

Age: 18Years - 75YearsAll GendersPhase 1Phase 2
14 locations
P

Actively Recruiting

Researchers are evaluating 9MW1911 in adults aged 40 to 75 who have been diagnosed with Chronic Obstructive Pulmonary Disease COPD for at least one year. This Phase II clinical trial is designed to assess how well 9MW1911 works and how safe it is for treating COPD. The study compares two different doses of 9MW1911 given intravenously with a placebo, and aims to better understand treatment effects on COPD flare-ups and lung function. Participants receive intravenous infusions of either 9MW1911 in one of two dose levels or a placebo every 28 days. Each treatment group includes 120 patients, all receiving stable standard care for COPD. The study lasts for 52 weeks of treatment, followed by safety and immune response monitoring up to 60 weeks. Researchers measure lung function, COPD exacerbations, quality of life, and other health markers during this period. During the study, participants will have regular visits for lung function tests, questionnaires about COPD symptoms and quality of life, blood tests, and safety assessments. These assessments occur at multiple time points, such as weeks 0, 4, 8, 12, 24, 36, and 52. The main outcome is the rate of moderate to severe COPD exacerbations over one year. Additional measures include lung function changes, time to first exacerbation, and biological markers. Safety and tolerability are followed for up to 60 weeks to ensure participant well-being throughout the trial.

Age: 40Years - 75YearsAll GendersPhase 2
51 locations
E

Actively Recruiting

Researchers are evaluating dapirolizumab pegol DZP as an additional treatment alongside standard care medications for people with moderately to severely active systemic lupus erythematosus SLE. The study aims to determine if DZP can provide meaningful long-term improvement in disease activity compared to placebo. This is a phase 3, randomized, double-blind, placebo-controlled trial sponsored by UCB Biopharma SRL. Participants are randomly assigned to receive either dapirolizumab pegol or a placebo throughout the treatment period. Both groups continue their standard of care medication during the trial. The treatment is administered at prespecified time points during the study, which lasts for 48 weeks. The study monitors disease activity and safety outcomes during this time. During the study, participants will attend regular visits to assess disease activity using measures such as the British Isles Lupus Assessment Group Disease Activity Index BILAG 2004 and the Systemic Lupus Erythematosus Disease Activity Index 2000 SLEDAI-2K. Researchers will also evaluate fatigue, glucocorticoid dose reduction, and record any treatment-emergent adverse events. Safety follow-up continues up to 54 weeks. Overall participation lasts nearly a year, including treatment and follow-up assessments.

Age: 16Years +All GendersPhase 3
245 locations
E

Actively Recruiting

Researchers are evaluating the efficacy and safety of AZD1163, a novel bispecific antibody, in adults with moderately-to-severely active rheumatoid arthritis RA. AZD1163 targets enzymes involved in protein citrullination, which leads to the production of harmful antibodies in RA. This Phase II, randomized, double-blind, placebo-controlled study focuses on adults with positive anti-citrullinated peptide antibodies ACPA who are already receiving standard treatments. Participants will be randomly assigned to one of four groups to receive subcutaneous injections of either one of three doses of AZD1163 or a placebo, all combined with their standard care including conventional synthetic disease-modifying antirheumatic drugs csDMARDs or tumor necrosis factor inhibitors TNFi with or without csDMARDs. The treatment period lasts 24 weeks, followed by a safety follow-up phase of 28 weeks. During the study, participants will undergo assessments including measures of disease activity using scores such as DAS28-CRP at 12 weeks. Additional evaluations will monitor response criteria, clinical disease activity indices, and the pharmacokinetics and immunogenicity of AZD1163 up to 24 weeks and during follow-up. Safety and efficacy will be closely monitored throughout the treatment and follow-up periods, with total participation lasting approximately 52 weeks.

Age: 18Years +All GendersPhase 2
147 locations
E

Actively Recruiting

Researchers are evaluating whether tenecteplase helps adults recover from an acute ischemic stroke when given more than 4.5 hours after the person was last seen well. This study focuses on people who had a stroke caused by a clot blocking a brain blood vessel and have imaging showing brain tissue that can still be saved. Participants are excluded if they are planned for a procedure to remove the clot. Participants are randomly placed into two groups. One group receives a single intravenous injection of tenecteplase, while the other group receives standard medical care. The trial compares these treatments to see if tenecteplase improves recovery when given later than the usual 4.5-hour window after stroke onset. Participants stay in the study for about three months, including roughly one week in the hospital. They undergo seven clinical visits or exams, with the last two likely done remotely from home. Doctors assess recovery using a scale that measures disability and dependence in daily life. They also monitor health and any side effects to compare outcomes between the two groups.

Age: 18Years +All GendersPhase 3
257 locations
A

Actively Recruiting

Researchers are evaluating the clinical effects and safety of Sodium Oligomannate GV-971 for treating mild to moderate Alzheimers Disease. This Phase 4 study aims to confirm how GV-971 works, monitor known side effects over long-term use, and identify any new adverse reactions to provide improved clinical guidance. Participants are randomly assigned to receive either GV-971 or a placebo, both given by mouth. The study lasts 36 weeks and uses a double-blind design where neither participants nor researchers know which treatment is given, ensuring unbiased results. The trial involves multiple centers and compares the two groups in parallel. During the study, participants will undergo assessments of cognitive and functional abilities using tools like ADAS-cog12 and ADCS-ADL23 at the start and after 36 weeks. Additional measures include MMSE, CIBIC-Plus, and NPI scores. Safety is monitored throughout, and the study tracks any adverse events. The total participation time is about 36 weeks from baseline.

Age: 50Years - 85YearsAll GendersPhase 4
50 locations

1-10 of 20

1